Thursday November 26 2009 | Biotechnology feed | All feeds
|
|
Prolexys Pharmaceuticals, Inc.
Download detailed PDF Members: Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company’s therapeutic focus is on cancer and cardiovascular indications where Prolexys has identified novel, druggable therapeutic targets. Small molecules that act at these targets have been identified and tested in cell and animal models of disease. Lead programs include a) PRLX82845, a compound with selective anti-tumor activity, b) PRLX8025, a compound for colon cancer, c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation
This page has been viewed 273 times since April 2007, the link to the organisation's website has been followed 51 times Search for more companies in Salt Lake City Search for more companies in Utah This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Prolexys Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||
|